LifeStance prices 22.25 million-share secondary offering at $12.35
LifeStance Health Group has priced an underwritten secondary offering of 22,250,000 shares of common stock at $12.35 a share, the outpatient mental health provider said in a statement dated Sept. 9. At the public offering price the block is worth roughly $275m.
The shares are being sold entirely by existing holders. According to the release, the selling stockholders will receive all of the proceeds from the offering, and LifeStance is not selling any shares and will not receive any proceeds. Barclays is acting as underwriter. The offering is expected to close on or about Sept. 11, subject to customary closing conditions, which means it is an agreed transaction rather than a completed one.
Running alongside the sale, LifeStance has agreed to purchase 2,000,000 shares from the underwriter at a price per share equal to the price per share the underwriter pays the selling stockholders — a net figure the company did not disclose separately. The release states the repurchase is conditioned upon completion of the offering and the satisfaction of other customary conditions. On the numbers in the release, the company is taking back about 9% of the stock moving in the transaction.
The company did not identify who is selling, describing the sellers only as "certain stockholders" of the company. That is standard drafting for a shelf takedown, and it leaves the composition of the block to be confirmed in the prospectus supplement and subsequent ownership filings.
Filing history supplies the context. A prospectus supplement filed with the Securities and Exchange Commission and dated Feb. 25, 2026 covered an earlier secondary offering in which TPG VIII Lynnwood Holdings Aggregation, L.P. sold 20,685,061 shares and entities affiliated with Summit Partners sold 4,314,939 shares, both at $7.01 a share, for a combined block of roughly 25 million shares.
That February document shows TPG's position falling from 160,711,618 shares, or 41.2% of the company, to 140,026,557 shares, or 36.6%, once the offering and a concurrent company buyback were taken into account. The Summit vehicles went from 33,524,715 shares, or 8.6%, to 29,209,776 shares, or 7.6%. LifeStance bought 7,000,000 shares in that transaction, worth about $49.07m at the offering price, using cash on hand.
Set against that, Wednesday's pricing is 76% above the February level. The comparison is between two negotiated block prices seven months apart rather than between screen prices, but it does indicate that a sponsor exit which was being executed at $7.01 in the winter is now being executed at a materially higher level.
The offering is being made off an automatic shelf registration statement, including a prospectus, that LifeStance filed with the SEC on May 21, 2024 and which became effective on filing, according to the pricing release.
On the underlying business, LifeStance reported total revenue of $435.4m for the quarter ended June 30, 2026 and net income of $23.6m, or $0.06 a diluted share on a GAAP basis, in its Form 10-Q for that period. For the six months to June 30 the company reported revenue of $838.8m and net income of $37.9m, or $0.10 a diluted share.
The same filing shows cash and cash equivalents of $225.9m at June 30 against term-loan borrowings of $275.5m, of which $259.0m was carried as long-term debt net of issuance costs and $14.5m as the current portion. The balance sheet shows 382.0 million shares outstanding at June 30, and the cover page of the filing reports 382,055,609 shares outstanding as of July 29.
The 10-Q also sets out a payor mix weighted to commercial insurers, which accounted for roughly 88% of revenue, with government payors near 7% and self-pay near 4%. Two individual payors were disclosed as concentrations, one at 14% and one at 15% of total revenue. That is a concentration worth noting: rate negotiations with a single large payer can move a full year of results in a business built on reimbursed clinician visits.
Two caveats sit on the deal itself. A secondary offering raises no new capital for the issuer, so LifeStance's balance sheet is unchanged by the sale apart from the cash it spends on the 2,000,000-share purchase. And the description of the company as one of the largest US providers of virtual and in-person outpatient mental health care is LifeStance's own characterisation of itself, carried in the release rather than independently established here.
